| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advisory Group recommendations on priorities for the IARC Monographs
|
Berrington de González, Amy
|
|
|
25 |
5 |
p. 546-548
|
artikel
|
| 2 |
Alternative approaches to risk–benefit balancing in immunotherapy
|
Ilhan, Yusuf
|
|
|
25 |
5 |
p. e178
|
artikel
|
| 3 |
Arsenic contamination and cancer risk in Bangladesh
|
Das, Manjulika
|
|
|
25 |
5 |
p. 538
|
artikel
|
| 4 |
Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial
|
Jimenez, Camilo
|
|
|
25 |
5 |
p. 658-667
|
artikel
|
| 5 |
Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial
|
Campbell, Matthew T
|
|
|
25 |
5 |
p. 649-657
|
artikel
|
| 6 |
Cancer and incarceration: a call for action
|
Richman, Ilana B
|
|
|
25 |
5 |
p. 530-531
|
artikel
|
| 7 |
Cancer incidence, treatment, and survival in the prison population compared with the general population in England: a population-based, matched cohort study
|
Lüchtenborg, Margreet
|
|
|
25 |
5 |
p. 553-562
|
artikel
|
| 8 |
Cancer Workforce Fund launched to address oncology workforce crisis
|
Wilkinson, Emma
|
|
|
25 |
5 |
p. 545
|
artikel
|
| 9 |
Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study
|
Turtle, Lance
|
|
|
25 |
5 |
p. 636-648
|
artikel
|
| 10 |
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study
|
Ercan, Ayse Bahar
|
|
|
25 |
5 |
p. 668-682
|
artikel
|
| 11 |
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
|
Houédé, Nadine
|
|
|
25 |
5 |
p. 531-533
|
artikel
|
| 12 |
Considerations for using potential surrogate endpoints in cancer screening trials
|
Webb, Alexis B
|
|
|
25 |
5 |
p. e183-e192
|
artikel
|
| 13 |
Correction to Lancet Oncol 2023; 24: 1094–108
|
|
|
|
25 |
5 |
p. e180
|
artikel
|
| 14 |
Curbing the climb in cancer incidence
|
The Lancet Oncology,
|
|
|
25 |
5 |
p. 529
|
artikel
|
| 15 |
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology
|
Marvaso, Giulia
|
|
|
25 |
5 |
p. e193-e204
|
artikel
|
| 16 |
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
|
Burris III, Howard A
|
|
|
25 |
5 |
p. 626-635
|
artikel
|
| 17 |
Environmental pollution and cancer risk in La Oraya, Peru
|
Das, Manjulika
|
|
|
25 |
5 |
p. 540
|
artikel
|
| 18 |
EPA ruling to ban chrysotile asbestos
|
Burki, Talha
|
|
|
25 |
5 |
p. 537
|
artikel
|
| 19 |
Evaluating cancer care in low-income and middle-income countries
|
Pari, Vrindha
|
|
|
25 |
5 |
p. e179
|
artikel
|
| 20 |
Expansion of radiotherapy access in Ethiopia
|
Das, Manjulika
|
|
|
25 |
5 |
p. 542
|
artikel
|
| 21 |
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
|
Rodriguez-Otero, Paula
|
|
|
25 |
5 |
p. e205-e216
|
artikel
|
| 22 |
1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic
|
Kirby, Tony
|
|
|
25 |
5 |
p. 536
|
artikel
|
| 23 |
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
|
Emmett, Louise
|
|
|
25 |
5 |
p. 563-571
|
artikel
|
| 24 |
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?
|
Wierman, Margaret E
|
|
|
25 |
5 |
p. 534-535
|
artikel
|
| 25 |
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
|
van der Voort, Anna
|
|
|
25 |
5 |
p. 603-613
|
artikel
|
| 26 |
Nigeria revitalises national cancer response with new initiatives
|
Adepoju, Paul
|
|
|
25 |
5 |
p. 544
|
artikel
|
| 27 |
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
|
Oaknin, Ana
|
|
|
25 |
5 |
p. 588-602
|
artikel
|
| 28 |
No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma
|
Voortman, Jens
|
|
|
25 |
5 |
p. 533-534
|
artikel
|
| 29 |
Olanzapine for chemotherapy-induced nausea and vomiting control
|
Radhakrishnan, Venkatraman
|
|
|
25 |
5 |
p. e174
|
artikel
|
| 30 |
Olanzapine for chemotherapy-induced nausea and vomiting control
|
Tsuruta, Seiji
|
|
|
25 |
5 |
p. e176
|
artikel
|
| 31 |
Olanzapine for chemotherapy-induced nausea and vomiting control
|
Sharma, Vinod
|
|
|
25 |
5 |
p. e175
|
artikel
|
| 32 |
Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply
|
Bajpai, Jyoti
|
|
|
25 |
5 |
p. e177
|
artikel
|
| 33 |
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
|
Machiels, Jean-Pascal
|
|
|
25 |
5 |
p. 572-587
|
artikel
|
| 34 |
Proposed bill to support assisted dying in France
|
Devi, Sharmila
|
|
|
25 |
5 |
p. e182
|
artikel
|
| 35 |
Protecting Caribbean patients diagnosed with cancer from compounding disasters
|
Ortiz, Ana Patricia
|
|
|
25 |
5 |
p. e217-e224
|
artikel
|
| 36 |
SSO 2024
|
Landman, Allison
|
|
|
25 |
5 |
p. 539
|
artikel
|
| 37 |
Study bolsters concerns about US FDA accelerated drug approvals
|
Furlow, Bryant
|
|
|
25 |
5 |
p. 543
|
artikel
|
| 38 |
The fate of sotorasib: a regulatory failure potentially harming patients
|
Ranganathan, Sruthi
|
|
|
25 |
5 |
p. 549-552
|
artikel
|
| 39 |
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
|
Fehm, Tanja
|
|
|
25 |
5 |
p. 614-625
|
artikel
|
| 40 |
UK tobacco and vapes bill one step closer
|
Venkatesan, Priya
|
|
|
25 |
5 |
p. 541
|
artikel
|
| 41 |
US EPA sets historic new restrictions on toxic PFAS in drinking water
|
Furlow, Bryant
|
|
|
25 |
5 |
p. e181
|
artikel
|
| 42 |
When leukaemia masquerades: the hidden syphilis diagnosis
|
Musicante, Meryl
|
|
|
25 |
5 |
p. e225
|
artikel
|
Tijdschrift beschrijving